(Z)-1-[3-[(dimethylamino)methyl]azetidin-1-yl]-3-[3-[3-(fluoromethyl)-5-(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]prop-2-en-1-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (Z)-1-[3-[(dimethylamino)methyl]azetidin-1-yl]-3-[3-[3-(fluoromethyl)-5-(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]prop-2-en-1-one
• 化学式: C₁₉H₂₁F₄N₅O
• 分子量: 411.4
• InChiKey: GPWRUTMNKXLZLF-ARJAWSKDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  54.3
• 氢给体数：
  0
• 氢受体数：
  8

文献信息

• [EN] METHODS OF PROMOTING WOUND HEALING USING CRM1 INHIBITORS<br/>[FR] PROCÉDÉS DE PROMOTION DE LA CICATRISATION D'UNE PLAIE À L'AIDE D'INHIBITEURS DE CRM1
  申请人：KARYOPHARM THERAPEUTICS INC

  公开号：WO2014144772A1

  公开（公告）日：2014-09-18

  The invention generally relates to the use of nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula (I) or a pharmaceutically acceptable salt thereof, wherein Ring A, X, R1, R2 and n are as defined and described herein, in a method for promoting wound healing in a subject.

  该发明通常涉及核转运调节剂的使用，例如CRM1抑制剂，更具体地涉及一种由结构式（I）表示的化合物或其药学上可接受的盐，在促进受试者伤口愈合的方法中，其中环A、X、R1、R2和n如本文所定义和描述。
• Methods of Promoting Wound Healing Using CRM1 Inhibitors
  申请人：KARYOPHARM THERAPEUTICS INC.

  公开号：US20160304500A1

  公开（公告）日：2016-10-20

  The invention generally relates to the use of nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula (I) or a pharmaceutically acceptable salt thereof, wherein Ring A, X, R 1 , R 2 and n are as defined and described herein, in a method for promoting wound healing in a subject.
• Nuclear Transport Modulators And Uses Thereof
  申请人：Karyopharm Therapeutics Inc.

  公开号：US20170137430A1

  公开（公告）日：2017-05-18

  The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by formula I: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.
• US9428490B2
  申请人：——

  公开号：US9428490B2

  公开（公告）日：2016-08-30